Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial.
Christopher J M WilliamsRichard GrayRobert K HillsMichael ShiresLiping ZhangZuo ZhaoTracie GardnerNancy SapanaraXiao-Meng XuIsaac BaiDongyao YanAndrea MuranyiSarah DanceFaranak AghaeiGemma HemmingsMichael HaleUday KurkureChristoph GuetterSusan D RichmanGordon HutchinsJenny F SeligmannNicholas P WestShalini SinghKandavel ShanmugamPhilip QuirkePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Recurrence rates in the high-risk CD3/CD8 groups are twice those in the low-risk groups. Proportional reductions with chemotherapy are similar, allowing NNTs derived in QUASAR to be updated using contemporary, nonrandomized data sets.